Beyond individual tumor types, the Tumor-Infiltrating Lymphocyte-Directed Anti-CTLA-4 and Anti-PD-1 Therapy for Immunotherapy-Naïve Solid Tumors (LAST trial) will be the first pan-tumor, TIL-based trial, evaluating cadonilimab, a bispecific anti-CTLA-4/PD-1 ICI, in patients with inflamed immune phenotypes. This evidence concerns the gene CTLA4 and neoplasm.